-
公开(公告)号：US11518805B2
公开(公告)日：2022-12-06
申请号：US16862981
申请日：2020-04-30
Inventor： Kyunglim Lee
IPC: C07K7/00 , C07K16/24 , A61K38/16 , A61K39/395 , C07K14/47 , A61K38/19 , A61P27/14 , C07K14/52 , A61K9/14 , A61K9/20 , A61K9/48 , A61K39/00
Abstract: The present invention relates to a receptor-binding domain of an IgE-dependent histamine releasing factor (HRF), and a use thereof, and more specifically, ascertains, as an HRF structural region, and a FL domain and an H2 domain which bind to a receptor of HRF existing in a cell membrane, ascertains the C-terminus domain of the HRF, and ascertains that a material binding thereto inhibits IL-8 secretion, thereby determining that the FL and H2 domains and the C-terminus domain can be utilized in: the development of a therapeutic agent for treatment and prevention of HRF-related disease including allergic diseases such as asthma, rhinitis, atopic dermatitis, and anaphylaxis; inflammatory diseases such as rheumatoid arthritis; and malaria, and a method for screening for the HRF-related diseases.
-
公开(公告)号：US11324807B2
公开(公告)日：2022-05-10
申请号：US15569659
申请日：2016-04-27
Applicant: Swedish Orphan Biovitrum AB (publ)
Inventor： Ebba Florin-Robertsson , Jonas Fransson , Barry D. Moore
IPC: A61K38/20 , A61K9/00 , A61K47/18 , A61K47/20 , A61P27/02 , A61P27/14 , A61P27/04 , A61K47/02 , A61K47/12 , A61K47/22 , A61K47/26
Abstract: The present invention relates to compositions comprising anakinra, buffer, and optionally at least one osmolyte and optionally further excipients. Further, the present invention relates to use of said compositions for treatment of for example ophthalmic disorders.
-
公开(公告)号：US11285081B2
公开(公告)日：2022-03-29
申请号：US16486490
申请日：2018-02-14
Applicant: SANTEN PHARMACEUTICAL CO., LTD.
Inventor： Sreenivasu Mudumba , Kedar Datar , Hiromitsu Shiono , Chun-jung Chu , Le An , Sudeep Rauser
IPC: A61J3/00 , A61K31/436 , B65D1/02 , A61P27/14 , A61P27/06 , A61P37/06 , B29L31/00 , A61K45/06 , B65D81/32 , A61J1/20
Abstract: In order to enable long-term stabilization of rapamycin contained in a liquid formulation, a formulation sealing vessel of the present invention includes: a sealed vessel body in which a liquid formulation containing 2% (w/w) rapamycin or a salt thereof, 94% (w/w) polyethylene glycol, and 4% (w/w) ethanol is sealed, the sealed vessel body having a volume of 0.1 mL to 1.0 mL, the liquid formulation containing no antioxidant, and the liquid formulation having a total volume of 0.02 mL to 1.0 mL.
-
4.发明申请公开(公告)号：US20210177798A1
公开(公告)日：2021-06-17
申请号：US16759014
申请日：2018-10-23
Inventor： Pierre CHAMBON
Abstract: Two enantiomers of a SElective Glucocorticoid Receptor Agonistic Modulator (SEGRAM) of Formula 1 or a derivative thereof; to a deuterated form of a SEGRAM of Formula 1 or a derivative thereof; and to the two deuterated enantiomers of a SEGRAM of Formula 1 or a derivative thereof: or a pharmaceutically acceptable salt, solvate and/or prodrug thereof.
The present invention also relates to a SEGRAM of Formula 1 or a derivative thereof, or a pharmaceutically acceptable enantiomer, deuterated form, salt, solvate and/or prodrug thereof, for use in the prevention or treatment of an inflammatory disorder in a subject in need thereof.-
公开(公告)号：US10703812B2
公开(公告)日：2020-07-07
申请号：US15382277
申请日：2016-12-16
Inventor： Kyunglim Lee , Dong Hae Shin , Mi-Sun Kim , Mi Young Kim , Jeehye Maeng , Hee-Won Lee
IPC: A61K38/16 , C07K16/24 , A61K39/395 , C07K14/47 , A61K38/19 , A61P27/14 , C07K14/52 , A61K9/14 , A61K9/20 , A61K9/48 , A61K39/00
Abstract: The present invention relates to a receptor-binding domain of an IgE-dependent histamine releasing factor (HRF), and a use thereof, and more specifically, ascertains, as an HRF structural region, and a FL domain and an H2 domain which bind to a receptor of HRF existing in a cell membrane, ascertains the C-terminus domain of the HRF, and ascertains that a material binding thereto inhibits IL-8 secretion, thereby determining that the FL and H2 domains and the C-terminus domain can be utilized in: the development of a therapeutic agent for treatment and prevention of HRF-related disease including allergic diseases such as asthma, bronchitis, chronic obstructive pulmonary disease, bronchiectasis, rhinitis, atopic dermatitis, hives (urticaria), hay fever, conjunctivitis, and anaphylaxis; inflammatory diseases such as bronchitis, pneumonia, arthritis, nephritis, psoriasis, dermatitis, Crohn's disease, enteritis, gingivitis, arteriosclerosis, coronary arteritis, hepatitis, Behcet's disease, bladder cancer, prostatitis, pyelonephritis, glomerulonephritis, osteomyelitis, thyroiditis, uveitis, abdominal cavity inflammation, meningitis, pulmonary fibrosis and rheumatoid arthritis; and malaria, and a method for screening for the HRF-related diseases.
-
Patent Agency Ranking
公开(公告)号：US10653661B2
公开(公告)日：2020-05-19
申请号：US15842063
申请日：2017-12-14
Applicant: GLENMARK SPECIALTY S.A.
Inventor： Neelima Khairatkar-Joshi , Abhay Kulkarni , Dinesh Pradeep Wale , Vikram M. Bhosale , Piyush Agarwal , Patrick Keohane , Sudeesh K. Tantry , Chad Oh
IPC: A61K31/335 , A61K31/573 , A61K9/00 , A61P27/14
Abstract: The present invention relates to a method of treating allergic rhinitis in a subject (e.g., a human) in need thereof comprising nasally administering to the subject an effective amount of a fixed-dose pharmaceutical composition comprising mometasone or its salt and olopatadine or its salt.
-
公开(公告)号：US20200030320A1
公开(公告)日：2020-01-30
申请号：US16484957
申请日：2018-02-09
Applicant: NITTO MEDIC CO., LTD.
Inventor： Mineo ONUKI
IPC: A61K31/495 , A61K9/08 , A61K9/00 , A61P11/02 , A61P27/14
Abstract: Provided is an aqueous composition for ophthalmic or nasal administration comprising levocetirizine or its salt. In one embodiment, the composition comprises levocetirizine or its salt at a levocetirizine concentration of 0.05-0.5% (w/v). The composition may further comprise a surface active agent and/or an organic acid salt.
-
公开(公告)号：US08785445B2
公开(公告)日：2014-07-22
申请号：US13141675
申请日：2009-12-18
Applicant: Adam Cook , Kevin W. Hunt , Robert Kirk Delisle , Todd Romoff , Christopher T. Clark , Ganghyeok Kim , Christopher P. Corrette , George A. Doherty , Laurence E. Burgess
Inventor： Adam Cook , Kevin W. Hunt , Robert Kirk Delisle , Todd Romoff , Christopher T. Clark , Ganghyeok Kim , Christopher P. Corrette , George A. Doherty , Laurence E. Burgess
IPC: C07D405/12 , A61K31/4433 , C07D241/20 , A61K31/497 , A61K31/501 , A61P11/06 , A61P27/14 , A61P17/00 , A61P29/00
CPC classification number: C07D405/12 , C07D405/14 , C07D413/12 , C07D417/12
Abstract: Compounds of Formula I: (I) in which A, A1, R1, R7a, R7b, R8 and R10 have the meanings given in the specification, are DP2 receptor inhibitors useful in the treatment of useful in the treatment and prevention of immunologic diseases, allergic diseases such as asthma, allergic rhinitis and atopic dermatitis, and other inflammatory diseases mediated by prostaglandin D2 (PGD2). The compounds of Formula I may also be useful in treating diseases or medical conditions involving the Th2 T cell via production of IL-4, IL-5 and/or IL-13.
Abstract translation: 其中A，A1，R1，R7a，R7b，R8和R10具有本说明书中给出的含义的式I化合物：（I）是可用于治疗和预防免疫疾病的DP2受体抑制剂， 过敏性疾病如哮喘，过敏性鼻炎和特应性皮炎，以及由前列腺素D2（PGD2）介导的其他炎性疾病。 式I化合物还可用于通过产生IL-4，IL-5和/或IL-13来治疗涉及Th2T细胞的疾病或医学病症。
-
公开(公告)号：US08518919B2
公开(公告)日：2013-08-27
申请号：US13294069
申请日：2011-11-10
Applicant: Phuong Grace Dang , Brian D. Lawrence , Gul Balwani , Alexander D. D'Addio
Inventor： Phuong Grace Dang , Brian D. Lawrence , Gul Balwani , Alexander D. D'Addio
CPC classification number: A61K47/26 , A61K9/0043 , A61K9/0048 , A61K9/0056 , A61K9/0073 , A61K9/7007 , A61K31/55 , A61K45/06 , Y02A90/22 , Y02A90/26 , A61K2300/00
Abstract: The present invention provides pharmaceutical compositions comprising azelastine, or a pharmaceutically acceptable salt or ester thereof including azelastine hydrochloride, and optionally one or more additional active agents. Preferred such compositions further comprise one or more pharmaceutically acceptable carriers or excipients that reduce the amount of post-nasal drip, and/or that minimize or mask the unpleasant bitter taste associated with post-nasal drip, of the compositions into the oral cavity, upon intranasal or ocular administration of the compositions. Especially effective excipients used in the compositions of the present invention are hypromellose as a viscosity modifier and sucralose as a taste-masking agent. The invention also provides methods of treating or preventing certain disorders, or symptomatic relief therefrom, by administering the compositions of the invention to a patient, e.g., for the symptomatic relief of allergic rhinitis, non-allergic vasomotor rhinitis, allergic conjunctivitis, as well as other disorders.
Abstract translation: 本发明提供包含氮卓斯汀或其药学上可接受的盐或酯的药物组合物，包括盐酸萘曲斯汀和任选的一种或多种另外的活性剂。 优选的这种组合物还包含一种或多种药学上可接受的载体或赋形剂，其减少鼻后滴液的量，和/或将组合物与鼻腔滴注相关的令人不快的苦味最小化或掩盖到口腔中 鼻内或眼部给药组合物。 用于本发明组合物中的特别有效的赋形剂是作为粘度调节剂的羟丙甲纤维素和作为掩味剂的三氯蔗糖。 本发明还提供了通过向患者施用本发明组合物，例如用于过敏性鼻炎，非过敏性血管舒缩性鼻炎，过敏性结膜炎以及 其他疾病。
-
公开(公告)号：US20130165419A1
公开(公告)日：2013-06-27
申请号：US13333534
申请日：2011-12-21
Applicant: Richard L. Lindstrom , Kamran Hosseini , Lyle M. Bowman
Inventor： Richard L. Lindstrom , Kamran Hosseini , Lyle M. Bowman
IPC: A61K31/573 , A61P27/02 , A61P31/12 , A61P31/04 , A61P27/12 , A61P27/06 , A61P35/00 , A61P33/02 , A61P31/10 , A61P29/00 , A61P27/14
CPC classification number: A61K31/573 , A61K9/0048 , A61K9/08 , A61K31/196 , A61K31/57 , A61K45/06 , A61K2300/00
Abstract: Compositions and systems for topical ophthalmic application, which include an aqueous mixture of steroidal and non-steroidal anti-inflammatory agents in a flowable mucoadhesive polymer, for treating inflammation and inflammatory conditions of the eye.
-
-
-
-
-
-
-
-
-
Search Results
426
records
(took 0.031 seconds)
